European Medicines Agency Watch [to 21 February 2015]
.
:: Major European research project on monitoring and evaluation of medicines concludes
16/02/2015
The European Medicines Agency (EMA) hosted and broadcast a symposium on 19 and 20 February to mark the conclusion of the five-year Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT) project.

PROTECT’s goal is to strengthen the monitoring of the benefit-risk of medicines marketed in Europe by developing innovative methods. It is a public-private partnership of 34 European partners with EMA as the coordinator and GSK as the deputy coordinator. It is funded by the Innovative Medicines Initiative Joint Undertaking; partners include national medicines authorities, academic institutions and pharmaceutical companies.

The European Medicines Agency (EMA. PROTECT results may significantly influence practices in pharmacovigilance and benefit-risk evaluation. Therefore, during 2015, EMA will systematically scrutinise PROTECT’s research outputs in order to identify priority results that are robust and which if implemented, have the greatest potential to positively impact public health.